Adcetris Earns Conditional Approval in Europe

European regulators have granted conditional approval to Seattle Genetics to begin marketing Adcetris (brentuximab vedotin) in member countries in the EC.

Regulators have approved Adcetris for two indications:

-- The treatment of adults with relapsed or refractory CD30-positive Hodgkin's lymphoma (HL) following autologous stem cell transplant (ASCT) or at least two prior therapies when ASCT or chemotherapy aren’t appropriate
-- The treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL)

Adcetris was granted accelerated approval in the United States in August of 2011, which means that Seattle Genetics is required to provide added clinical trial data to confirm the risk-benefit assessment of the treatment.

In Europe it will be no different since the EC's conditional marketing authorization requires much the same things as accelerated approval in the U.S.

Adcetris is an antibody drug conjugate (ADC) that includes an anti-CD30 monoclonal antibody attached to the cytotoxic microtubule disrupting agent monomethyl autistatin E.

Source: Seattle Genetics

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap